10/31/14 GILD 112.00 Gilead Sciences $GILD Hit a 5
Post# of 162
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 107.78 (+0.74), VRTX: 112.64 (+1.79), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)
IBD 50 Caps Impressive 2-Week Rally
at Investor's Business Daily - Fri Oct 31, 5:47PM CDT
The IBD 50 just capped its best two-week performance in more than three years -- a run that's produced a batch of breakouts. The index rallied 9.4% over the past two weeks. That's the best two-week period since July 2011, when the IBD 50 roared...
ODFL: 72.87 (+0.51), AAP: 146.96 (+1.25), AKRX: 44.55 (+0.91), ILMN: 192.58 (-0.84), NXPI: 68.66 (+3.25), CDW: 30.84 (+0.71), CELG: 107.09 (+0.15), BIDU: 238.77 (+1.76), GILD: 112.00 (-2.22), JAZZ: 168.84 (-0.98), FLT: 150.56 (+8.01), FL: 56.01 (+0.16), AAPL: 108.00 (+1.02), AVGO: 86.25 (+3.86)
Final Glance: Biotechnology companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
Fundamentals, Technicals Still Intact At Gilead Sciences
at Investor's Business Daily - Fri Oct 31, 4:36PM CDT
Some analysts called Gilead Sciences' third-quarter earnings report on Oct. 28 "sloppy." But make no mistake: It's still a company in growth mode. And its weekly chart doesn't look bad either. Gilead's (GILD) earnings per share slightly missed...
GILD: 112.00 (-2.22)
Midday Glance: Biotechnology companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
AbbVie Beats Q3 Earnings Estimates, Raises Guidance
at Investor's Business Daily - Fri Oct 31, 1:25PM CDT
Big pharma AbbVie beat analysts' Q3 estimates and raised its guidance Friday, sending its stock up 4% to an all-time high above 63. AbbVie's (ABBV) earnings rose 9% over the year-earlier quarter to 89 cents a share, 12 cents above analysts'...
IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), SHPG: 199.80 (+0.38), AMGN: 162.18 (+0.60), ABBV: 63.46 (+2.28)
Early Glance: Biotechnology companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 112.00 (-2.22), AMGN: 162.18 (+0.60), CELG: 107.09 (+0.15)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 107.78 (+0.74), NEE: 100.22 (+0.31), V: 241.43 (+4.78), GILD: 112.00 (-2.22), DUK: 82.15 (-0.14), EXC: 36.59 (-0.11), MRK: 57.94 (+0.63), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28), DTE: 82.16 (+0.17), SO: 46.36 (-0.09), MA: 83.75 (+0.62)
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $115.51
Comtex SmarTrend(R) - Fri Oct 31, 8:58AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $113.06 today and have reached the first resistance level of $115.51. Should the shares continue to rise, the resistance pivots of $116.81 and $120.56 will be of interest.
GILD: 112.00 (-2.22)
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.72 (+0.46), TTWO: 26.45 (+1.18), BIIB: 321.08 (+0.08), GILD: 112.00 (-2.22), CRL: 63.16 (+0.35), REGN: 393.72 (+0.92), CELG: 107.09 (+0.15)
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.77 (+1.67), BIIB: 321.08 (+0.08), HON: 96.12 (+0.53), FB: 74.99 (+0.88), BMY: 58.19 (-0.79), MGM: 23.25 (+0.27), ATK: 116.96 (+6.77), YRCW: 21.44 (+3.24), UPS: 104.91 (+1.62), SLB: 98.66 (+1.04), CELG: 107.09 (+0.15), WPRT: 6.17 (+0.12), SBUX: 75.56 (-1.76), TTWO: 26.45 (+1.18), DO: 37.71 (-0.94), ETP: 64.43 (+0.41), GILD: 112.00 (-2.22), ARR: 3.96 (-0.01), CMG: 638.00 (-1.68), MPEL: 27.14 (+0.78), WNC: 10.30 (+0.81), CRL: 63.16 (+0.35), AAPL: 108.00 (+1.02), REGN: 393.72 (+0.92)
5 Things McKesson Corporation's Management Wants You to Know
Keith Speights, The Motley Fool - Motley Fool - Thu Oct 30, 5:23PM CDT
Now that the dust has settled after McKesson Corporation 's second-quarter financial results were announced on Tuesday, it's time to look past the numbers. Yes, McKesson beat expectations for earnings and revenue -- but the real story is what's...
MCK: 203.41 (-0.07), GILD: 112.00 (-2.22), RAD: 5.25 (+0.07)
Netflix and Gilead Will See More Gains, Says Thornburg Value Manager
at The Street - Thu Oct 30, 4:54PM CDT
Gilead shares have had a tremendous run this year, but the valuation remains cheap considering its sales potential in the area of Hepatitis C.
NFLX: 392.77 (+13.76), PAHC: 25.92 (+0.27), GILD: 112.00 (-2.22)
Veeva Systems Flies High On Cloud For Life Sciences
at Investor's Business Daily - Thu Oct 30, 4:31PM CDT
Before founding software company Veeva Systems in 2007, Peter Gassner was certain of two things. He wanted the technology to be cloud-based and to address critical issues for a specific industry. He decided to focus on life sciences. "We could have...
VEEV: 29.78 (+0.99), IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), ORCL: 39.05 (+0.55), CRM: 63.99 (+2.27), NVS: 92.69 (+0.74)
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 3.13%
Comtex SmarTrend(R) - Thu Oct 30, 3:35PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $110.60 to a high of $114.35. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $114.13 on volume of 13.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 112.00 (-2.22)
SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 3.13% Gain
Comtex SmarTrend(R) - Thu Oct 30, 3:34PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $110.60 to a high of $114.35. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $114.13 on volume of 13.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 112.00 (-2.22)
Most active Nasdaq-traded stocks
AP - Thu Oct 30, 12:17PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MU: 33.09 (+1.27), GILD: 112.00 (-2.22), FB: 74.99 (+0.88), CDTI: 3.12 (-0.79), ARCP: 8.87 (-0.55), MSFT: 46.95 (+0.90), INTC: 34.01 (+1.43), GRPN: 7.31 (+1.32), AAPL: 108.00 (+1.02), CSCO: 24.47 (+0.39), RFMD: 13.01 (+0.94)